Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18181803 | 1.00 | PARP1 (0.58) | PARP1MAOAMAOBHTR1ABRD4 | |
| SCHEMBL19122972 | 0.78 | PARP1 (0.56) | PARP1MAOAMAOBHTR1ABRD4 | |
| SCHEMBL13074639 | 0.78 | PARP1 (0.56) | PARP1MAOAMAOBHTR1ABRD4 | |
| SCHEMBL31304842 | 0.78 | PARP1 (0.37) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL18474153 | 0.77 | PARP1 (0.54) | PARP1MAOAMAOBHTR1ABRD4 | |
| SCHEMBL4596031 | 0.77 | PARP1 (0.54) | PARP1MAOAMAOBHTR1ABRD4 | |
| SCHEMBL4596860 | 0.77 | PARP1 (0.36) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5544990 | 0.77 | PARP1 (0.58) | PARP1MAOAMAOBHTR1ABRD4 | |
| SCHEMBL5544997 | 0.77 | MAOA (0.62) | PARP1MAOAMAOBHTR1A | |
| SCHEMBL20997664 | 0.77 | PARP1 (0.54) | PARP1MAOAMAOBHTR1ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4231806-A1 | ORGANIC LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2023-08-23 | — | — | EP | disclosed |
| US-10251827-B2 | Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst | L'OREAL (FR) | 2019-04-09 | — | — | US | disclosed |
| US-20160128922-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | L'OREAL (FR) | 2016-05-12 | — | — | US | disclosed |
| US-20160128922-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | L'OREAL (FR) | 2016-05-12 | — | — | US | disclosed |
| WO-2014202787-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | L'OREAL (FR) | 2014-12-24 | — | — | WO | disclosed |
| US-8350028-B2 | 2-aminoquinolines | HOFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2262774-B1 | 2-aminoquinolines as 5-HT5A receptor antagonists, their manufacture and pharmaceutical compositions thereof | HOFFMANN LA ROCHE (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-7989628-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| CN-101959557-A | 2-aminoquinolines as 5-HT5A receptor antagonists | HOFFMANN LA ROCHE | 2011-01-26 | — | — | CN | disclosed |
| EP-2262774-A2 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-0902028-A1 | Tetrazoline herbicides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0724580-A1 | BENZANILIDE DERIVATIVES AS 5HT-1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011243-A1 | BENZANILIDE DERIVATIVES AS 5HT-1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-04-27 | — | — | WO | disclosed |
| EP-0079683-B1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-06 | — | — | EP | disclosed |
| US-4577011-A | Miticidal 2-(2-alkyl-2,3-dihydrobenzofuran-7-yl)-N-alkoxy-N-alkyl-diazenecarboxamides | SHELL OIL COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4554283-A | Aphicidal 3-(2-alkyl-2,3-dihydrobenzofuran-7-yl)-5-(R,R1 -amino)-1,3,4-oxadiazol-2(3H)-ones | SHELL OIL COMPANY (US) | 1985-11-19 | — | — | US | disclosed |
| US-4514211-A | HERBICIDES, PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| EP-0079683-A2 | Herbicidal sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251827-B2 | Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst | KRT18, CYB5R3, CBR3 | PARP1 1125/4885MAOA 554/4885MAOB 180/4885 |
| US-20160128922-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | KRT18, CYB5R3, CBR3 | PARP1 888/4885MAOA 535/4885MAOB 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.